Media headlines about Abbott Laboratories (NYSE:ABT) have been trending somewhat positive on Wednesday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Abbott Laboratories earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news articles about the healthcare product maker an impact score of 47.0167302535017 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:

ABT has been the topic of several recent research reports. TheStreet upgraded shares of Abbott Laboratories from a “c+” rating to a “b” rating in a research report on Monday, July 3rd. Royal Bank Of Canada reissued a “buy” rating on shares of Abbott Laboratories in a research note on Monday, May 15th. Jefferies Group LLC reissued a “buy” rating and set a $51.00 target price (up previously from $50.00) on shares of Abbott Laboratories in a research note on Friday, May 12th. Stifel Nicolaus reissued a “buy” rating and set a $49.00 target price on shares of Abbott Laboratories in a research note on Tuesday, April 18th. Finally, Cowen and Company reissued a “buy” rating and set a $48.00 target price on shares of Abbott Laboratories in a research note on Thursday, April 13th. Six equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Abbott Laboratories currently has a consensus rating of “Buy” and a consensus target price of $51.93.

Shares of Abbott Laboratories (ABT) traded down 0.23% during trading on Wednesday, hitting $48.77. 4,102,919 shares of the stock traded hands. The company has a market cap of $84.63 billion, a PE ratio of 68.31 and a beta of 1.07. The company has a 50 day moving average of $49.10 and a 200-day moving average of $45.36. Abbott Laboratories has a 1-year low of $37.38 and a 1-year high of $51.13.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. The firm had revenue of $6.64 billion during the quarter, compared to the consensus estimate of $6.63 billion. During the same quarter in the prior year, the firm posted $0.55 EPS. The business’s revenue was up 24.5% on a year-over-year basis. On average, equities analysts anticipate that Abbott Laboratories will post $2.49 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, August 15th. Shareholders of record on Friday, July 14th will be given a dividend of $0.265 per share. This represents a $1.06 dividend on an annualized basis and a yield of 2.17%. The ex-dividend date is Wednesday, July 12th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 149.30%.

In other Abbott Laboratories news, insider Sharon J. Bracken sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $49.16, for a total transaction of $98,320.00. Following the completion of the transaction, the insider now owns 28,806 shares of the company’s stock, valued at approximately $1,416,102.96. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Jared Watkin sold 552 shares of the company’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $47.97, for a total value of $26,479.44. Following the transaction, the insider now directly owns 47,090 shares of the company’s stock, valued at approximately $2,258,907.30. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 218,702 shares of company stock valued at $10,149,733. Insiders own 0.76% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Abbott Laboratories (NYSE:ABT) Share Price” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/10/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-abbott-laboratories-nyseabt-share-price.html.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Insider Buying and Selling by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Stock Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related stocks with our FREE daily email newsletter.